The company believes YKP10811 possesses a range of efficacy in both the upper and lower GI tract and an improved safety profile.
The program is expected to develop a drug with once-a-day oral dosing and improved efficacy for the treatment of chronic constipation and other reduced gastrointestinal (GI) motility disorders.
The company expects to launch the product in 2016, if the Phase II trials and coming Phase III trials are successful.
SK Biopharmaceuticals drug development business vice president Jeong Woo Cho said YKP10811 was shown to be safe in Phase 1 clinical studies in healthy volunteers.
"In particular, at the highest tested dose level of 1,350mg, the drug did not show any significant signs of drowsiness or sedation," Woo Cho added.